Tagrisso is only first-line treatment for EGFR-mutated NSCLC to deliver median overall survival of over three years

This article was originally published here

Results showed a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint for Tagrisso versus gefitinib or erlotinib, both of which were previous standard-of-care (SoC)

The post Tagrisso is only first-line treatment for EGFR-mutated NSCLC to deliver median overall survival of over three years appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply